🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Alemtuzumab is an antibody that reduces the strength of the immune system t...
Status
Recruiting
Location
Cincinnati Children's Hospital Medical Center
Start Date
2023-01-11
Trial ID
NCT05501756
Treatments Being Tested
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total...
Status
Terminated
Location
OHSU Knight Cancer Institute
Start Date
2003-05
Trial ID
NCT00416884
Treatments Being Tested
Alemtuzumab is an anti CD52 monoclonal antibody. The CD52 antigen is presen...
Status
Completed
Location
Saint Antoine Hospital, Hematology Unit
Start Date
2006-10
Trial ID
NCT00773149
Treatments Being Tested
Anti-rejection medicines, also known as immunosuppressive drugs, are prescr...
Status
Completed
Location
Duke University Health System
Start Date
2018-07-30
Trial ID
NCT03504241
The purpose of this study is to compare the safety and efficacy of differen...
Status
Completed
Location
Multiple Locations
Start Date
2005-05
Trial ID
NCT00113269
Treatments Being Tested
This study will evaluate the safety and effectiveness of a genetically engi...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Start Date
2005-07-21
Trial ID
NCT00217594
Treatments Being Tested
The aim of this study to evaluate the safety and efficacy of a nonmyeloabla...
Status
Recruiting
Location
Alberta Children's Hospital
Start Date
2017-07-05
Trial ID
NCT03214354
Treatments Being Tested
The goal of this clinical research study is to find out how well Campath (a...
Status
Terminated
Location
UT MD Anderson Cancer Center
Start Date
2008-08
Trial ID
NCT00771602
Treatments Being Tested
The purpose of this study was to assess whether a new drug, Nulojix® (belat...
Status
Terminated
Location
University of Alabama
Start Date
2011-09
Trial ID
NCT01436305
Treatments Being Tested
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarab...
Status
Completed
Location
Memorial Sloan-Kettering Cancer Center
Start Date
2001-07
Trial ID
NCT00027560